Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma

Carrie A Thompson, Herve Ghesquieres, Matthew J. Maurer, James R Cerhan, Pierre Biron, Stephen Maxted Ansell, Catherine Chassagne-Clément, David J. Inwards, Thérèse Gargi, Patrick Bruce Johnston, Emmanuelle Nicolas-Virelizier, William R. Macon, Marie Peix, Ivana Micallef, Catherine Sebban, Grzegorz S Nowakowski, Luis F. Porrata, George J. Weiner, Thomas Elmer Witzig, Thomas Matthew HabermannBrian K. Link

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Methods Patients with newly diagnosed DLBCL and treated with anthracycline-based immunochemotherapy were identified from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence and the Léon Bérard Cancer Center, Lyon, France. In those with relapse, details at relapse and outcomes were abstracted from records.

Purpose: We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL) from the United States and confirmed our results in an independent cohort of patients from France.

Results: 680 individuals with DLBCL were identified from the MER, 552 (81%) of whom achieved remission after induction. 112 of the 552 patients (20%) suffered a relapse. The majority (64%) of relapses were identified before a scheduled follow-up visit. Surveillance imaging detected DLBCL relapse before clinical manifestations in nine out of 552 patients (1.6%) observed after therapy. In the Lyon cohort, imaging identified asymptomatic DLBCL relapse in four out of 222 patients (1.8%). There was no difference in survival after DLBCL relapse in patients detected at scheduled follow-up versus before scheduled follow-up in both the MER (P =.56) and Lyon cohorts (P =.25).

Conclusion: The majority of DLBCL relapses are detected outside of planned follow-up, with no difference in outcome in patients with DLBCL detected at a scheduled visit compared with patients with relapse detected outside of planned follow-up. These data do not support the use of routine surveillance imaging for follow-up of DLBCL.

Original languageEnglish (US)
Pages (from-to)3506-3512
Number of pages7
JournalJournal of Clinical Oncology
Volume32
Issue number31
DOIs
StatePublished - Nov 1 2014

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Recurrence
Molecular Epidemiology
Therapeutics
France
Remission Induction
Anthracyclines
Lymphoma
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. / Thompson, Carrie A; Ghesquieres, Herve; Maurer, Matthew J.; Cerhan, James R; Biron, Pierre; Ansell, Stephen Maxted; Chassagne-Clément, Catherine; Inwards, David J.; Gargi, Thérèse; Johnston, Patrick Bruce; Nicolas-Virelizier, Emmanuelle; Macon, William R.; Peix, Marie; Micallef, Ivana; Sebban, Catherine; Nowakowski, Grzegorz S; Porrata, Luis F.; Weiner, George J.; Witzig, Thomas Elmer; Habermann, Thomas Matthew; Link, Brian K.

In: Journal of Clinical Oncology, Vol. 32, No. 31, 01.11.2014, p. 3506-3512.

Research output: Contribution to journalArticle

Thompson, CA, Ghesquieres, H, Maurer, MJ, Cerhan, JR, Biron, P, Ansell, SM, Chassagne-Clément, C, Inwards, DJ, Gargi, T, Johnston, PB, Nicolas-Virelizier, E, Macon, WR, Peix, M, Micallef, I, Sebban, C, Nowakowski, GS, Porrata, LF, Weiner, GJ, Witzig, TE, Habermann, TM & Link, BK 2014, 'Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma', Journal of Clinical Oncology, vol. 32, no. 31, pp. 3506-3512. https://doi.org/10.1200/JCO.2014.55.7561
Thompson, Carrie A ; Ghesquieres, Herve ; Maurer, Matthew J. ; Cerhan, James R ; Biron, Pierre ; Ansell, Stephen Maxted ; Chassagne-Clément, Catherine ; Inwards, David J. ; Gargi, Thérèse ; Johnston, Patrick Bruce ; Nicolas-Virelizier, Emmanuelle ; Macon, William R. ; Peix, Marie ; Micallef, Ivana ; Sebban, Catherine ; Nowakowski, Grzegorz S ; Porrata, Luis F. ; Weiner, George J. ; Witzig, Thomas Elmer ; Habermann, Thomas Matthew ; Link, Brian K. / Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. In: Journal of Clinical Oncology. 2014 ; Vol. 32, No. 31. pp. 3506-3512.
@article{bbc6f8a427524d42acc7b0f8662fca8c,
title = "Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma",
abstract = "Methods Patients with newly diagnosed DLBCL and treated with anthracycline-based immunochemotherapy were identified from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence and the L{\'e}on B{\'e}rard Cancer Center, Lyon, France. In those with relapse, details at relapse and outcomes were abstracted from records.Purpose: We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL) from the United States and confirmed our results in an independent cohort of patients from France.Results: 680 individuals with DLBCL were identified from the MER, 552 (81{\%}) of whom achieved remission after induction. 112 of the 552 patients (20{\%}) suffered a relapse. The majority (64{\%}) of relapses were identified before a scheduled follow-up visit. Surveillance imaging detected DLBCL relapse before clinical manifestations in nine out of 552 patients (1.6{\%}) observed after therapy. In the Lyon cohort, imaging identified asymptomatic DLBCL relapse in four out of 222 patients (1.8{\%}). There was no difference in survival after DLBCL relapse in patients detected at scheduled follow-up versus before scheduled follow-up in both the MER (P =.56) and Lyon cohorts (P =.25).Conclusion: The majority of DLBCL relapses are detected outside of planned follow-up, with no difference in outcome in patients with DLBCL detected at a scheduled visit compared with patients with relapse detected outside of planned follow-up. These data do not support the use of routine surveillance imaging for follow-up of DLBCL.",
author = "Thompson, {Carrie A} and Herve Ghesquieres and Maurer, {Matthew J.} and Cerhan, {James R} and Pierre Biron and Ansell, {Stephen Maxted} and Catherine Chassagne-Cl{\'e}ment and Inwards, {David J.} and Th{\'e}r{\`e}se Gargi and Johnston, {Patrick Bruce} and Emmanuelle Nicolas-Virelizier and Macon, {William R.} and Marie Peix and Ivana Micallef and Catherine Sebban and Nowakowski, {Grzegorz S} and Porrata, {Luis F.} and Weiner, {George J.} and Witzig, {Thomas Elmer} and Habermann, {Thomas Matthew} and Link, {Brian K.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1200/JCO.2014.55.7561",
language = "English (US)",
volume = "32",
pages = "3506--3512",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "31",

}

TY - JOUR

T1 - Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma

AU - Thompson, Carrie A

AU - Ghesquieres, Herve

AU - Maurer, Matthew J.

AU - Cerhan, James R

AU - Biron, Pierre

AU - Ansell, Stephen Maxted

AU - Chassagne-Clément, Catherine

AU - Inwards, David J.

AU - Gargi, Thérèse

AU - Johnston, Patrick Bruce

AU - Nicolas-Virelizier, Emmanuelle

AU - Macon, William R.

AU - Peix, Marie

AU - Micallef, Ivana

AU - Sebban, Catherine

AU - Nowakowski, Grzegorz S

AU - Porrata, Luis F.

AU - Weiner, George J.

AU - Witzig, Thomas Elmer

AU - Habermann, Thomas Matthew

AU - Link, Brian K.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Methods Patients with newly diagnosed DLBCL and treated with anthracycline-based immunochemotherapy were identified from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence and the Léon Bérard Cancer Center, Lyon, France. In those with relapse, details at relapse and outcomes were abstracted from records.Purpose: We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL) from the United States and confirmed our results in an independent cohort of patients from France.Results: 680 individuals with DLBCL were identified from the MER, 552 (81%) of whom achieved remission after induction. 112 of the 552 patients (20%) suffered a relapse. The majority (64%) of relapses were identified before a scheduled follow-up visit. Surveillance imaging detected DLBCL relapse before clinical manifestations in nine out of 552 patients (1.6%) observed after therapy. In the Lyon cohort, imaging identified asymptomatic DLBCL relapse in four out of 222 patients (1.8%). There was no difference in survival after DLBCL relapse in patients detected at scheduled follow-up versus before scheduled follow-up in both the MER (P =.56) and Lyon cohorts (P =.25).Conclusion: The majority of DLBCL relapses are detected outside of planned follow-up, with no difference in outcome in patients with DLBCL detected at a scheduled visit compared with patients with relapse detected outside of planned follow-up. These data do not support the use of routine surveillance imaging for follow-up of DLBCL.

AB - Methods Patients with newly diagnosed DLBCL and treated with anthracycline-based immunochemotherapy were identified from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence and the Léon Bérard Cancer Center, Lyon, France. In those with relapse, details at relapse and outcomes were abstracted from records.Purpose: We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL) from the United States and confirmed our results in an independent cohort of patients from France.Results: 680 individuals with DLBCL were identified from the MER, 552 (81%) of whom achieved remission after induction. 112 of the 552 patients (20%) suffered a relapse. The majority (64%) of relapses were identified before a scheduled follow-up visit. Surveillance imaging detected DLBCL relapse before clinical manifestations in nine out of 552 patients (1.6%) observed after therapy. In the Lyon cohort, imaging identified asymptomatic DLBCL relapse in four out of 222 patients (1.8%). There was no difference in survival after DLBCL relapse in patients detected at scheduled follow-up versus before scheduled follow-up in both the MER (P =.56) and Lyon cohorts (P =.25).Conclusion: The majority of DLBCL relapses are detected outside of planned follow-up, with no difference in outcome in patients with DLBCL detected at a scheduled visit compared with patients with relapse detected outside of planned follow-up. These data do not support the use of routine surveillance imaging for follow-up of DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=84911476792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911476792&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.55.7561

DO - 10.1200/JCO.2014.55.7561

M3 - Article

C2 - 25267745

AN - SCOPUS:84911476792

VL - 32

SP - 3506

EP - 3512

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -